



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

**Transvaginal and Transurethral Radiofrequency Tissue
Remodeling for Urinary Stress Incontinence**

Policy #: 296
Category: Medicine

Latest Review Date: August 2021
Policy Grade: B

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

For dates of service on or after March 24, 2020:

Blue Advantage will treat transvaginal radiofrequency bladder neck suspension and/or transurethral radiofrequency tissue remodeling as a treatment of urinary stress incontinence as a non-covered benefit and as investigational.

Effective for dates of service February 26, 2018 through March 23, 2020, refer to LCD L36954.

Effective for dates of service prior to February 26, 2018:

Blue Advantage will treat transvaginal radiofrequency bladder neck suspension and/or transurethral radiofrequency tissue remodeling as a treatment of urinary stress incontinence as a non-covered benefit and as investigational.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Urinary stress incontinence (SUI), defined as the involuntary loss of urine from the urethra due to an increase in intra-abdominal pressure, is a common condition, affecting 6.5 million women in the United States. Conservative therapy includes behavior modifications, pelvic floor muscle exercises, or periurethral bulking agents such as collagen. Various surgical options are considered when conservative therapy fails, including most prominently various different types of bladder suspension procedures, which intends to reduce bladder neck and urethra hypermobility by tautening the endopelvic fascia.

The use of nonablative levels of radiofrequency energy has been investigated as a non-surgical technique to shrink and stabilize the endopelvic fascia, thus improving the support for the urethra and bladder neck. An incision is made through the vagina lateral to the urethra, exposing the endopelvic fascia. Radiofrequency energy is then applied over the endopelvic fascia in a slow, sweeping manner, resulting in blanching and shrinkage of the tissue. The procedure is also known as radiofrequency micro-remodeling or radiofrequency collagen denaturation.

KEY POINTS:

The most recent update was with a review of the literature through August 26, 2021.

Summary of Evidence

For individuals receiving transvaginal or transurethral radiofrequency for tissue remodeling for urinary stress incontinence, the evidence includes small prospective and retrospective studies, and one RCT. Relevant outcomes include quality of life, improvement of symptoms, and treatment morbidity. There remains insufficient evidence from well-conducted randomized controlled trials that either transvaginal or transurethral radiofrequency improves the net health outcome compared to a sham procedure or another treatment for stress urinary incontinence. Larger studies with long-term follow-up, identification of the patient population that might benefit from the procedure and independent replication are needed. There is minimal evidence within the peer-reviewed literature that provides support for the use of transvaginal radiofrequency surgery or transurethral radiofrequency tissue micro-remodeling. The efficacy and long-term effectiveness of these modalities for the treatment of urinary incontinence has not been determined. The evidence is insufficient to determine the health effects of this technology.

Practice Guidelines and Position Statements

The American College of Obstetricians and Gynecologists (ACOG)

In 2015 (reaffirmed in 2018), ACOG published practice bulletin Number 155 – Urinary Incontinence in Women. The recommendations on treating urinary incontinence in women do not mention transvaginal or transurethral radiofrequency remodeling.

American Urological Association (AUA) / Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction (SUFU).

In 2017, the AUA and SUFU published a guideline for the Surgical Treatment of Female Stress Urinary Incontinence. The recommendations do not mention transvaginal or transurethral radiofrequency remodeling.

U.S. Preventive Task Force Recommendations

N/A

KEY WORDS:

Transvaginal radiofrequency bladder neck suspension, transurethral radiofrequency tissue remodeling, urinary stress incontinence, SUI, radiofrequency, micro-remodeling, radiofrequency collagen denaturation

APPROVED BY GOVERNING BODIES:

The SURx Transvaginal System received clearance to market through the U.S. Food and Drug Administration (FDA) 510(k) process in 2002. According to the FDA, the device “is indicated for shrinkage and stabilization of female pelvic tissue for treatment of Type II stress urinary

incontinence due to hypermobility in women not eligible for major corrective surgery”. This device is no longer marketed in the United States.

Novasys Medical received clearance to market the Renessa transurethral RF system through the U.S. FDA 510(k) process in July 2005. The device “is indicated for the transurethral treatment of female stress urinary incontinence due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy”.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

not consider investigational if FDA approved and will be reviewed for medical necessity.

CURRENT CODING:

CPT Codes:

53899	Unlisted procedure, urinary system
53860	Transurethral radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence

REFERENCES:

1. American College of Obstetricians and Gynecologists (ACOG). Urinary incontinence in women 2005 (currency reaffirmed in 2018). Available online at: www.guideline.gov.
2. American Urological Association / Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction. Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline (2017). Available online at: [https://www.auanet.org/guidelines/stress-urinary-incontinence-\(sui\)-guideline](https://www.auanet.org/guidelines/stress-urinary-incontinence-(sui)-guideline).
3. Appell RA and Davila GW. Treatment options for patients with suboptimal response to surgery for stress urinary incontinence. Current Medical Research and Opinion, February 2007; 23(2): 285-292.
4. Appell RA, et al. Transurethral radiofrequency energy collagen micro-remodeling for the treatment of female stress urinary incontinence. Neurourological Urodynamics 2006; 25(4): 331-336.
5. Appell RA, Singh G, Klimberg IW, et al. Nonsurgical, radiofrequency collagen denaturation for stress urinary incontinence: Retrospective three-year evaluation. Expert Rev Med Devices 2007; 4(4): 455-461.
6. Appell RA. Transurethral collagen denaturation for women with stress urinary incontinence. Current Urology Reports, September 2008; 9(5): 373-379.

7. Buchsbaum GM, et al. Outcome of transvaginal radiofrequency for treatment of women with stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction*, March 2007; 18(37): 263-265.
8. Dmochowski RR, et al. Transvaginal radio frequency treatment of the endopelvic fascia: A prospective evaluation for the treatment of genuine stress urinary incontinence. *Journal of Urology* 2003; 169(3): 1028-1032.
9. Elser DM, et al. Nonsurgical transurethral collagen denaturation for stress urinary incontinence in women: 12-Month results from a prospective long-term study. *Journal of Minimally Invasive Gynecology* 2008 (article in press).
10. Elser DM, et al. Nonsurgical transurethral collagen denaturation for stress urinary incontinence in women: 18-month results from a prospective long-term study. *Neurourology and Urodynamics*. 2010; 29(8):1424-8.
11. Elser DM, et al. Stress urinary incontinence in women: What options lie between traditional therapies and surgery? *Women's Health* 2007; 3(6): 725-733.
12. Elser DM, Mitchell GK, Miklos JR et al. Nonsurgical transurethral radiofrequency collagen denaturation: results at three years after treatment. *Adv Urol* 2011; 2011:872057.
13. Fulmer BR, et al. Acute and long-term outcomes of radio frequency bladder neck suspension. *Journal of Urology* 2002; 167(1): 141-145.
14. IOM (Institute of Medicine). 2011. *Clinical Practice Guidelines We Can Trust*. Washington, DC: The National Academies Press.
15. Ismail SI. Radiofrequency remodeling of the endopelvic fascia is not an effective procedure for urodynamic stress incontinence in women. *International Journal of Pelvic Floor Dysfunction*, September 2008; 19(9); 1205-1209.
16. Juma S and Appell RA. Nonsurgical transurethral radiofrequency treatment of stress urinary incontinence in women. *Women's Health*, May 2007, Vol. 3, NO. 3, pp. 291-299.
17. Karliner L; California Technology Assessment Forum. Radiofrequency micro-remodeling for the treatment of female stress urinary incontinence. October 2008. Available online at: www.ctaf.org/content/general/detail/930. Last accessed February 2012.
18. Lenihan JP, et al. Oral and local anesthesia in the non-surgical radiofrequency energy treatment of stress urinary incontinence. *Journal of Minimally Invasive Gynecology* 2006, Vol. 12, No. 5, pp. 415-419.
19. Lenihan JP. Comparison of the quality of life after non-surgical radiofrequency energy tissue micro-remodeling in premenopausal and postmenopausal women with moderate-to-severe stress urinary incontinence. *American Journal of Obstetrics and Gynecology* 2005; 192(6): 1995-1998.
20. Lordelo P, Vilas BA, Sodre D, et al. New concept for treating female stress urinary incontinence with radiofrequency. *Int Braz J Urol*. 2017 Sep-Oct;43(5):896-902.
21. McDougall EM, et al. Laparoscopic bladder neck suspension fails the test of time. *Journal of Urology* 1999; 162(6): 2078-2081.
22. Moore RD, et al. Minimally invasive treatment for female stress urinary incontinence. *Expert Review of Obstetrics and Gynecology*, March 2008, Vol. 3, No. 2, pp. 257-272.

23. Ross JW, et al. A prospective multisite study of radiofrequency bipolar energy for treatment of genuine stress incontinence. *Journal of American Association of Gynecologic Laparoscopy* 2002; 9(4): 493-499.
24. Sotomayor M, et al. Transurethral delivery of radiofrequency energy for tissue microremodeling in the treatment of stress urinary incontinence. *Internal Urogynecologic Journal Pelvic Floor Dysfunction* 2003; 14(6): 373-379.
25. Sotomayor M, et al. Twelve-month results of nonsurgical radiofrequency energy microremodeling for stress incontinence. *International Urogynecology Journal and Pelvic Floor Dysfunction* 2005; 16(3): 192-196.
26. Stachowicz AM, Hoover ML, Karram MM. Clinical utility of radiofrequency energy for female genitourinary dysfunction: past, present, future. *Int Urogynecol J.* 2021 Jun;32(6):1345-1350.
27. Wells WG, et al. Use of in-office anesthesia during non-surgical radiofrequency collagen denaturation for stress urinary incontinence. *Current Medical Research and Opinions* 2007, Vol. 23, No. 6, pp. 1279-1284.

POLICY HISTORY:

Adopted for Blue Advantage, January 2007

Available for comment January 29-March 4, 2007

Medical Policy Group, February 2009

Medical Policy Group, March 2010

Medical Policy Group, December 2010

Medical Policy Group, February 2011

Available for comment February 2 – March 18, 2011

Medical Policy Group, July 2011

Medical Policy Group, March 2013

Medical Policy Group, February 2018

Medical Policy Group, April 2020: Reinstated effective March 24, 2020.

Medical Policy Group, August 2021

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.